The Real Drivers of GLP-1 Growth

The obesity medication market is approaching a structural inflection point, with projections suggesting a peak valuation of $190 billion across obesity and diabetes treatments. Current penetration remains remarkably low, with only 6% of eligible U.S. patients and 2% of international patients utilizing GLP-1 therapies. Five primary drivers are accelerating this adoption: the transition from injectables to oral medications, expanded Medicare access for older populations, increased employer insurance coverage, and global expansion into price-sensitive markets like China and Brazil. Furthermore, clinical innovation is extending the use of these drugs to treat cardiovascular and kidney diseases. By 2035, global eligibility could reach 1.3 billion people, potentially reducing U.S. calorie consumption by 1.6%. This shift represents a long-term transformation in chronic disease management that will create significant ripple effects across the food, retail, and healthcare service industries.